Abstract:OBJECTIVE:To investigate the inhibitory effects of RNA silencing via plasmid-mediated vascular endothelial growth factor (VEGF) shRNA on proliferation of glioma cells in vitro and in vivo.METHODS:pEGFP-H1/VEGF vector plasmid containing enhanced green fluorescent protein (EGFP) gene and expressing VEGF shRNA was constructed. The EGFP expression was detected by fluorescent microscopy and flow cytometry. Glioma cells of the line U251 were cultured and divided into 3 groups to be transfected with blank vector, pEGFP/H1plasmid, and pEGFP-H1/VEGF respectively. RT-PCR was used to detect the mRNA expression of VEGF in the supernatants of the culture media. The protein expression of VEGF in the supernatant was detected by ELISA. The cell growth was observed with MTT method. Fifteen nude rats were randomly divided into 3 equal groups to be transplanted with U251 cells and pEGFP-H1, U251 cells and pEGFP-H1/VEGF, and U251 cells only as blank control group. The growth of glioma was observed every day. 30 days after the rats were killed and the tumors were taken out to be examined.RESULTS:Twenty-four hours after transplantation, fluorescence microscopy showed great numbers of U251 cells that expressed green fluorescence in both the pEGFP-H1 group and pEGFP-H1/VEGF group. Flow cytometry showed that the rates of green fluorescent protein positive cells were 68.37% and 65.29% in these 2 groups (P > 0.05). MTT method showed no significant difference in the effect on cell growth among the 3 groups (all P > 0.05). PCR showed that the VEGF mRNA expression was significantly inhibited in the pEGFP-H1/VEGF group in comparison with those in the blank control group and the group transfected with pEGFP-H1 (both P < 0.05). The concentration of VEGF protein of the U251 cells transfected with pEGFP-H1/VEGF was 530 ng/L +/- 118 ng/L, significantly lower than those of the control group (2571 ng/L +/- 572 ng/L) and the group transfected with pEGFP-H1 (2402 ng/L +/- 310 ng/L, by 77.9%) (both P < 0.01). Tumor could be touched 13 days after transplantation in the rats of pEGFP-H1/VEGF group, markedly later than in the other 2 groups. Thirty days after, the weight and volume of tumor were 0.5 g +/- 0.4 g and 401 mm(3) +/- 272 mm(3) respectively in the rats of pEGFP-H1/VEGF group, both significantly lower than those of the control group and pEGFP-H1 group (1.7 g +/- 0.4 g and 1573 mm(3) +/- 330 mm(3); and 1.5 g +/- 0.7 g and 1430 mm(3) +/- 382 mm(3)) (all P < 0.01).CONCLUSION:The successfully constructed shRNA targeting at VEGF efficiently decreases the VEGF expression of the glioma cells in vitro and suppresses the growth of glioma cells in vivo.

Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF.

Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

RNA interference targeting human FAK and EGFR suppresses human non-small-cell lung cancer xenograft growth in nude mice

VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice.

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma.

Influences of Over-Expression of VEGF-C and Its Inhibition on Biological Characteristics of NCI-H446 Human Small-Cell Lung Cancer Cells

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.

[Effect of VEGFR1 Gene Silencing by Shrna on Proliferation, Migration and Apoptosis of U937 Line].

Inhibition effect of siRNA on VEGF-C in patients with lung square cancer

Anti-Angiogenic Efficacy of 5 '-Triphosphate Sirna Combining Vegf Silencing and Rig-I Activation in Nsclcs

VEGF-specific siRNAs modified with 2′-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model

Vascular Endothelial Growth Factor Shrna Mediated by Pegfp-H1 Vector Plasmid Effectively Inhibits Glioma Proliferation: an Experimental Study

Low-Molecular Weight Chitosan/Vascular Endothelial Growth Factor Short Hairpin Rna for the Treatment of Hepatocellular Carcinoma

VEGF Sirna Delivered by Polycation Liposome-Encapsulated Calcium Phosphate Nanoparticles for Tumor Angiogenesis Inhibition in Breast Cancer

Knockdown of VEGF-A expression in neuroblastoma cell line SH-SY5Y by RNA interference

[Short Hairpin RNA Silencing of Vascular Endothelial Growth Factor, Telomerase Reverse Transcriptase, and Bcl-xl Expression in Human Laryngeal Squamous Carcinoma Xenografted in Nude Mice].

Effect of Blocking VEGF, Htert and Bcl-xl by Multiple Shrna Expression Vectors on the Human Laryngeal Squamous Carcinoma Xenograft in Nude Mice.

Apoptosis of Non-Small Cell Lung Cancer A549 Cells by Silencing EGFR with RNA Interference